Skip to content
Clinical Trials – home
CzechiaBack to Czechia

Clinical trials in Chocen – page 18

582 clinical trials in Chocen, Czechia across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

CzechiaOur site in CzechiaKlinickeTesty.cz(opens in a new tab)
Chocen at a glance
582
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

582 trials in Chocen

Open in trial search

Colitis ulcerative+1

Not yet recruiting

Study of ABBV-701 and Risankizumab Combination vs Monotherapy in Adults with Moderately to Severely Active Crohn’s Disease or Ulcerative Colitis

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Colitis ulcerative+1

Not yet recruiting

Study of risankizumab plus anti‑α4β7 integrin antibody versus each alone in adults with moderately to severely active Crohn’s disease or ulcerative colitis

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Type 2 diabetes mellitus

Not yet recruiting

Phase 3 Study of Maridebart Cafraglutide versus Semaglutide as Add‑on to Metformin (± SGLT‑2 Inhibitor) in Adults with Type 2 Diabetes Not Controlled by Metformin

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Amgen Inc.

Endometrial cancer

Not yet recruiting

Maintenance Treatment Study of gsk5733584 with dostarlimab or pembrolizumab in patients with mismatch repair proficient advanced or recurrent endometrial cancer

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Myelodysplastic syndrome

Not yet recruiting

Study of Bexmarilimab with Azacitidine versus Placebo with Azacitidine in Treatment‑Naïve Higher‑Risk Myelodysplastic Syndrome Patients

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Bexmarilimab
  • Sponsor:Faron Pharmaceuticals Oy

Malignant peritoneal neoplasm+2

Not yet recruiting

A Phase 3 Study of Raludotatug Deruxtecan With or Without Bevacizumab as Maintenance Therapy in Patients With Platinum‑Sensitive Recurrent Ovarian Cancer

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Daiichi Sankyo Inc.

Diabetic retinal oedema

Not yet recruiting

Efficacy and Safety of Intravitreal MK-8748 Compared with Aflibercept in Adults with Diabetic Macular Edema

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Merck Sharp & Dohme LLC

Randomized phase III study of AAA817 plus an androgen receptor pathway inhibitor in adult men with PSMA‑positive metastatic castration‑resistant prostate cancer

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Novartis Pharma AG

Multiple sclerosis

Not yet recruiting

Long‑Term Safety and Tolerability of Frexalimab Drug Combination in Adults with Multiple Sclerosis

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years
  • Substances:Colestyramine
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Breast cancer+2

Not yet recruiting

Gedatolisib with drug combination versus standard therapy as first‑line treatment for patients with advanced HR‑positive HER2‑negative breast cancer

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Celcuity Inc.

Dermatitis atopic

Not yet recruiting

Study of the safety and effectiveness of TRIV-573 injections in adults with moderate to severe atopic dermatitis

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Sponsor:Triveni Bio Inc.

Anaemia+1

Not yet recruiting

Study of Elritercept (TAK‑226) with Ruxolitinib vs Placebo in Patients with Myelofibrosis and Anemia on Ruxolitinib Therapy

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Elritercept
  • Sponsor:Takeda Development Center Americas Inc.

Other cities in Czechia

The busiest research cities in the country

All 150 cities in Czechia

Clinical research in Chocen

What the registry says about research in the country

01 Migraine Research

Innovative studies focusing on preventive treatments for various types of migraines, including menstrual, episodic, and chronic forms. Research explores new therapeutic approaches using medications like atogepant and Dysport®.

  • Menstrual Migraine Prevention
  • Episodic Migraine Management
  • Long-term Prevention Strategies

Multiple comparative studies evaluating treatment effectiveness and patient tolerability.

02 Neurodegenerative Disorders

Comprehensive research into neurodegenerative conditions, particularly focusing on Alzheimer's Disease and Parkinson's Disease. Studies include evaluation of novel therapeutic compounds for disease management.

  • Alzheimer's Disease Psychosis
  • Early-stage Alzheimer's Treatment
  • Parkinson's Disease Management

Trials aim to assess both short and long-term treatment efficacy and safety profiles.

03 Neurological Conditions

Advanced research in multiple sclerosis and chronic pain management, including studies on innovative treatments for relapsing-remitting MS and chronic back pain conditions.

  • Multiple Sclerosis Therapy
  • Chronic Pain Management
  • Non-opioid Pain Solutions

Focus on developing alternative treatment options and improving patient outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.